Imperial spin-out Veryan raises £3.6M for stent technology

Funding

Veryan Holdings Ltd has raised £3.6 million from a syndicate led by new investor Seroba Kernel, with existing investors Imperial Innovations, Oxford Capital Partners Ltd and NESTA. 

The money will be used for further development and a pivotal clinical trial of Veryan’s BioMimics 3-dimensional stent technology.

The stents have a 3-dimensional helical geometry, which generates a swirling blood flow and has been shown to significantly reduce the incidence of restenosis or re-narrowing of blood vessels in pre-clinical experiments.  In addition, Veryan has shown that the 3D geometry confers significant mechanical benefits. The BioMimics 3D stents are more flexible, kink- and fracture-resistant than traditional stents. The concept was originally conceived by Colin Caro at Imperial College, London.

While the stents will initially be developed for repairing peripheral vessels, the BioMimics 3D technology will be developed for all vascular stent applications.

Veryan has recently commenced a first-in-human and CE Mark study at Herz Zentrum, Bad Krozingen, Germany, led by Thomas Zeller, a recognised global expert in vascular medicine.  As well as providing supporting data for achievement of CE Mark status, this study will evaluate the clinical performance of the BioMimics 3D technology against a contemporary control stent, to assess a number of differentiating features of the Veryan stents.